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Objective: Early diagnosis and treatment initiation in childhood tuberculous meningitis (TBM) 
remains sub-optimal and contributes significantly to morbidity and mortality in this age group, 
especially in TB endemic areas. We aimed to describe the evolution of lumbar CSF parameters 
analyzed serially, to determine if re-sampling would influence the diagnostic accuracy of 
childhood TBM. 
Methods: We performed a retrospective observational study which included children with 
suspected TBM that were prospectively enrolled in several TBM research studies, at Tygerberg 
Hospital, Cape Town, South Africa, over a 30-year period. A data collection sheet was used to 
compare demographic, clinical and diagnostic characteristics on admission and subsequent repeat 
CSF parameters at weeks 1, 2 and 3. 
Results:  Of 318 children with suspected TBM, 53(17%) patients had ‘definite’ TBM and 
265(83%) patients had ‘probable’ TBM. Serial CSF analysis demonstrated a decrease in mean 
lymphocyte (143 to 49/µL) and neutrophil count (53 to 9/µL) over the 3-week period. Mean CSF 
protein also showed a gradual decline (3.29 to 1.85g/L) with a rise in mean CSF glucose (1.89 to 
2.72 mmol/L) three weeks after initiating treatment. A total of 230 (72%) patients were identified 
that had atypical CSF trends; an increase in CSF lymphocyte, neutrophil and protein count after 
TBM treatment initiation. A history of prolonged illness >5days (p=0.01) and initial CSF 
neutrophil predominance (p<0.01) were associated with an atypical increase in serial CSF 
lymphocyte count, while a positive tuberculin skin test (p=0.05) and initial CSF lymphocyte 
predominance (p<0.01) were associated with an atypical increase in serial neutrophil count. 
Admission CSF protein level >1g/L (p<0.01) predicted an atypical serial increase in CSF protein. 
According to the uniform research case definition for TBM, 14% of patients with “possible” 
TBM, would have improved their diagnostic status to “probable” TBM after repeat CSF analysis. 
Conclusion: Repeat lumbar CSF in TBM suspects can demonstrate different trends over time. 
The typical trend is a gradual decline in CSF lymphocyte, neutrophil, and protein count whilst 
the CSF glucose rise steadily.  It is not abnormal for the CSF lymphocyte, neutrophil, and protein 
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count to rise initially after treatment initiation, which can be seen as atypical for TBM. Although 
serial lumbar CSF analysis improves the diagnosis of childhood TBM when the uniform TBM 
research case definition’s scoring system is applied, it does not improve early diagnosis and 
outcome and could cause confusion if an atypical trend is found.  




Mikpunte: Vroeë diagnose en behandeling van tuberkuleuse breinvliesontsteking in kinders bly 
sub optimaal en dra betekenisvol by tot morbiditeit en mortaliteit, veral in hoë TB-belaste nasies. 
Ons het beoog om die verandering in serebrospinale vog (SSV) parameters oor ‘n periode te 
beskryf om sodoende te bepaal of herhaal lumbale punksie ‘n merkwaardige invloed sal hê in die 
diagnose van kinder tuberkuleuse breinvliesontsteking. 
Metodes: Retrospektiewe ontleding van 318 kinders met ‘n suspisie van tuberkuleuse 
breinvliesontsteking oor ‘n 30 jaar periode, by die Tygerbergse Hospitaal, Kaapstad, Suid-Afrika. 
Demografiese, kliniese en diagnostiese eienskappe met opname, asook herhaal SVV ontleding 1, 
2 en 3 weke later, is met mekaar vergelyk. 
Uitslae: Uit die 318 kinders met ‘n suspisie van tuberkuleuse breinvliesontsteking is 53(17%) 
gevalle bakteriologies bevestig en 265(83%) geïdentifiseer as waarskynlik tuberkuleuse 
breinvliesontsteking. SSV ontleding oor die 3-week periode het ‘n toename in gemiddelde 
limfosiet (143 na 49/µL) en neutrofiel telling (53 na 9/µL) getoon. Die gemiddelde proteïen 
konsentrasies het ook gelydelik afgeneem (3.29 to 1.85g/L) terwyl die SSV glukose vermeerder 
het oor die periode (1.89 na 2.72 mmol/L). Atipiese SSV patrone is gevind in 230 (72%) pasiënte 
na aanvang van behandeling, dit sluit in ‘n toename in SSV limfosiet, neutrofiel en proteïen 
telling. ‘n Geskiedenis van verlenge siekte >5 dae (p=0.01) en oorheersende SSV neutrofiele 
(p<0.01) was geassosieer met atipiese toename in SSV limfosiet telling, terwyl ‘n positiewe 
tuberkulien vel toets (p=0.05) en oorheersende SSV limfosiet (p<0.01) telling geassosieer was 
met atipiese toename in SSV neutrofiel telling. Aanvanklike proteïen konsentrasie >1g/L 
(p<0.01) was geassosieer met ‘n atipiese toename in SSV proteïen. Volgens die univorme 
navorsings gevalsdefinisie van tuberkuleuse meningitis, sou 14% van pasiënte met “moontlike” 





Gevolgtrekking:  Herhaal SSV in kinders met die suspisie van tuberkuleuse breinvliesontsteking  
kan verskillende patrone wys. Die klassieke SSV patroon toon ‘n afname in limfosiet, neutrofiel 
en proteïen konsentrasies, met ‘n toename in SSV glucose. Aanvanklike toename in SSV limfosiet, 
neutrofiel en proteïen konsentrasies, na aanvang van behandeling, is wel bekend.  Hierdie beeld 
kan as atipiese gesien word vir tuberkuleuse breinvliesontsteking. Alhoewel herhaal SSV die 
diagnose van tuberkuleuse breinvliesontsteking verbeter wanneer die univorme navorsings 
gevalsdefiniëring van tuberkuleuse meningitis gebruik word, dra dit nie by tot vroeër diagnose en 
beter uitkomste in kinders met tuberkuleuse breinvliesontsteking, en kan ‘n atipiese SSV patroon 
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Chapter 1: Introduction  
Tuberculous meningitis (TBM) is one of the most severe complications of tuberculosis and 
frequently occurs in children. Diagnostic uncertainty and treatment initiation remains a problem 
in childhood TBM resulting in substantial neurological morbidity or death. TBM is classically 
described as a subacute lymphocytic meningitis but the variety of clinical presentation, non-
specific symptoms, and young age at presentation, together with the limitation and challenges of 
diagnostic techniques available, all contribute in clouding the diagnosis. The development of a 
uniform research case definition has significantly contributed to guide clinicians and researchers 
to standardize a diagnosis for TBM. 
 
Diagnosis can neither be made or excluded on clinical grounds and is dependent on cerebrospinal 
fluid (CSF) analysis. Typical CSF findings in TBM suspects have been well-described but 
atypical CSF findings are commonly found. The diagnosis is regularly based only on clinical and 
preliminary cerebrospinal fluid (CSF) findings without any definitive microbiologic confirmation 
of Mycobacterium tuberculosis. 
 
Minimal data exist on the evolution of CSF changes, as determined by serial analysis, in 
childhood TBM. Knowledge of serial changes in the CSF parameters of children with TBM 
could possibly increase both the sensitivity and specificity in the diagnosis of TBM in children.  
 
By analyzing the changes in all lumbar CSF parameters on admission, week 1, week 2 and week 
3, one can possibly determine normal CSF evolution in patients with “probable” and “definite” 
TBM. This can assist and guide healthcare workers with a reference point, aiding in the diagnosis 
of childhood TBM. By assessing the atypical CSF trends, one can possibly identify which clinical 






Chapter 2: Literature review  
 
According to the World Health Organization (WHO) 2015 Global Tuberculosis (TB) Report, 
mortality in TB has fallen 47% since 1990 due to improved diagnosis and treatment. The TB 
incidence has also declined and is currently 18% lower than in 2000.1 An estimated 9.6 million 
people developed TB in 2014, of whom approximately one tenth are children. In South Africa, 
extrapulmonary TB accounts for 10 % of TB cases and children under 15 years contribute 10% 
of the total TB caseload.1 
 
Despite recent advances, TB remains a global threat. Early diagnosis and treatment initiation in 
children with tuberculous meningitis (TBM) remains sub-optimal, contributing significantly to 
an increased mortality and morbidity. 
 
Tuberculous meningitis represents 1% of all cases of TB. This number is disproportionately 
small, compared to the resultant morbidity and mortality.2 Young children and patients with 
immunodeficiency, mostly HIV co-infection and cancer, are at increased risk of developing 
TBM. Other factors, amongst others, that contributed to the development of TB are malnutrition, 
anaemia, advanced immune suppression and frequent TB exposure.3-5 The peak age for TBM 
incidence is <5 years.6-8A large South African retrospective study of children diagnosed with 
TBM found that 82% of children were < 5 years of age.7 In the Western Cape Province of South 
Africa, TBM is the most common and most devastating form of paediatric bacterial meningitis.9 
 
TBM is caused by Mycobacterium tuberculosis (M.tb), an organism with a lipid-rich cell wall. 
Rich and McCordock proposed the 2-step model for the pathogenesis of CNS TB. According to 
their model, based on autopsy findings, the majority of TBM cases had a single caseous focus 
(Rich’s focus) that could be found from which, when ruptured, bacilli could spread to the 
subarachnoid space.10 This has influenced the understanding of the pathogenesis of TBM, 







TBM is typically a subacute disease, mostly with an insidious onset causing non-specific 
symptoms, delaying the early recognition and diagnosis. A prominent clinical feature of TBM is 
the sub-acute duration of symptoms, typically >6 days.7, 12-14 TBM may also present acutely, or 
conversely have a chronic presentation with symptom duration ranging from 3 days to 6 
months.15 For clinicians to make an early diagnosis of TBM they should have a high index of 
diagnostic suspicion when faced with a child with non-specific symptoms and signs of possible 
neurological involvement.  
 
In the prodromal phase of TBM, one or more of low-grade fever, malaise, headache, dizziness, 
vomiting, poor feeding and growth faltering, cough, irritability, and/or personality changes can 
persist for several weeks. Following the non-specific prodromal stage, children with TBM 
develop more central nervous system (CNS) specific symptoms including neck stiffness, 
depressed level of consciousness, raised intracranial pressure, motor deficit and cranial 
neuropathies. When TBM is allowed to progress without treatment, coma will ensue. Seizures, in 
contrast to adults, are commonly seen in children with TBM, occurring in up to half of pediatric 
cases. 7, 12,14,15 A history of recent close contact with an adult source-case with TB is usually 
found in half of children (30%-53%), more frequently than when compared to adult 
patients.7,14,15 
 
Staging of the severity of TBM is based on the refined British Medical Research Council 
(BMRC) criteria. The staging criteria are as follows: 
 Stage I) Glasgow coma scale (GCS) of 15, without focal neurological deficit, 
Stage IIa) GCS of 15 with focal neurological deficit 
Stage IIb) GCS of 14-11 with or without focal neurological deficit  
Stage III) GCS < 11 with or without focal neurological deficit.16,17 
 
The signs and symptoms of stage І TBM disease are non-specific and similar to those of the 
primary infection rather than of neurological disease, commonly leading to missed diagnosis.18 
The majority of patients present with stage II or III TBM, with very poor outcome.7,15 
 




symptoms sometimes complicates it further by not distinguishing TBM from other forms of 
meningitis, especially partially-treated pyogenic meningitis, resulting in diagnostic and treatment 
delay.13, 19 
 
Despite many recent advances, diagnostic uncertainty remains a problem in childhood TBM. The 
diagnosis is regularly based only on clinical and preliminary cerebrospinal fluid (CSF) findings 
without definitive microbiologic confirmation of M.tb being available. Clinicians are often 
reluctant to start a patient, especially a child, on months of treatment without firm evidence of 
disease.  
 
The non-specific clinical features of the disease, the low sensitivity of conventional 
microbiology due to the paucibacillary nature of CSF20, and the lack of viable alternative 
diagnostic methods, all contribute to the diagnostic difficulty. A uniform case definition for TBM 
has enabled standardized TBM diagnosis for research purposes, especially in view of the 
limitation and challenges of diagnostic techniques available. Patients are stratified as having 
definite, probable or possible TBM using their clinical presentation together with the laboratory 
and radiological findings.21 
 
Lumbar CSF analysis is essential to the diagnosis of TBM. Characteristic lumbar CSF findings 
of TBM include: 1) clear and colorless appearance 2) increased leucocyte count of 10-500 
cells/µL 3) lymphocyte predominance of >50% 4) raised protein (>1.0 g/L) and 5) decreased 
glucose concentration (absolute value < 2.2 mmol/L and/or CSF-plasma ratio <50%).7,13,19,21-23 
Atypical CSF findings are common, including normal CSF cell count, protein and/or glucose 
levels, and even a  neutrophil predominance.13  Differentiating tuberculous meningitis from other 
forms of bacterial meningitis in TB-endemic environments can be challenging.13,19 For this 
reason clinicians often repeat a lumbar puncture to obtain CSF for analysis, especially if there is 
diagnostic uncertainty.  
 
The CSF findings are further complicated due to the inconsistency between lumbar and 
ventricular CSF in patients with non-communicating hydrocephalus. Ventricular CSF may record 





TBM is a chronic inflammatory response and CSF therefore takes weeks to normalize whilst 
rapid normalization is expected in non- tuberculous meningitis. CSF changes following initiation 
of anti-tuberculous treatment in children are not well-described. Previous adult studies that have 
examined serial CSF changes in patients with TBM found that: 1) the CSF normalizes over time, 
but the rate is variable ranging from 1-32 months 2) CSF glucose normalizes rapidly 3) CSF 
lymphocyte count and protein concentration changes slowly 4) CSF neutrophil count rapidly 
normalizes 5) CSF can temporarily worsen after anti-tuberculous treatment is initiated, i.e. CSF 
leucocyte count rises during the first 7 days, and 6) there is no correlation between the rate of 
change in CSF and TBM stage or the clinical response of the patient.25-27 These changes in the 
CSF profile provide an opportunity to increase the diagnostic accuracy of TBM. Repeat CSF 
analysis may provide valuable clinical guidance when deciding between TBM or an alternate 
cause of meningitis. If both CSF neutrophil count and glucose do not serially improve, it should 
be considered atypical for TBM and an alternative diagnosis, or drug-resistant strain of M.tb 
should be considered.28 
 
Corticosteroids not only improve clinical outcome and mortality rate in tuberculous meningitis 
but significantly lower CSF protein and globulin levels after 1 month of treatment and cause a 
steadier rise in CSF glucose levels compared to a non-steroid therapy group.29 Serial CSF cell 
counts, however, are not affected by adjuvant steroid therapy.29 
 
HIV modifies CSF characteristics in tuberculous meningitis. HIV-infected patients with TBM 
has a higher frequency of CSF characteristics that indicate a non-inflammatory CSF (absence of 
pleocytosis) and lower CSF protein levels, but similar CSF glucose levels when compared to 
non-infected patients.20 With HIV co-infection, there is a higher frequency of multidrug-resistant 
strains (MDR) which contributes significantly to the increase in mortality rate (63.3% vs 
17.5%).30 
 
Mycobacterial DNA may be detectable in the CSF for up to a month following initiation of  
treatment, while the sensitivity of CSF smear and culture decreases rapidly.31 The diagnosis of 
“definite” TBM, remains mycobacteriological confirmation in the CSF by microscopic 




amplification test for M.tb.21 It is well-recognized that the sensitivity of acid-fast bacilli staining 
and positive mycobacterial CSF culture depends on the number and volume of CSF samples 
obtained for analysis. A single sample has low sensitivity, 20%–40%.32 Two studies found that 
the sensitivity of positive mycobacterial CSF culture improved from 53% to 83%, after 
examining multiple samples of CSF.33-34  
 
In 2013, the WHO recommended that Xpert MTB/RIF® be used for rapid diagnosis in 
preference to conventional microscopy and culture as the initial diagnostic test in all TBM 
suspects.35 Caution, however, is advised especially due to low sensitivities, and it is 
recommended that larger CSF volumes are sampled.36A study by Solomons et al. found that 
more than one commercial nucleic-acid amplification test incrementally increased CSF 
diagnostic accuracy in childhood TBM.37 It would not be illogical to perform commercial 
nucleic-acid amplification tests on serial CSF samples in order to improve overall sensitivity and 
specificity. 
 
The outcome in TBM can only be improved through early diagnosis and treatment initiation, 
which can be aided by developing novel diagnostic tests and refining existing diagnostic 
methods. Research in childhood TBM is lacking on the evolution of CSF changes over time, as 





Chapter 3: Aim of the investigation 
 
3.1 Research justification: 
Childhood TBM remains a devastating disease and a global threat, especially in a TB endemic 
area like the Western Cape Province of South Africa. The majority of children diagnosed with 
TBM are <5 years of age.  Demographic, clinical, and social factors have been identified which 
contributes to the increased risk of developing childhood TBM.  
 
Despite many advances, diagnostic uncertainty remains a problem in childhood TBM. The non-
specific clinical features of the disease, the low sensitivity of conventional microbiology due to 
the small numbers of bacilli in the CSF, and the lack of viable alternative diagnostic methods, all 
contribute to the diagnostic difficulty. This results in delay of treatment initiation and disease 
progression. The majority of patients unfortunately present with advanced stage disease, with 
very poor outcome. 
 
The outcome in TBM can be improved through early diagnosis and treatment initiation, which 
can be aided by developing novel diagnostic tests and refining existing diagnostic methods. 
 
Previous adult studies that have examined serial CSF changes following initiation of anti-
tuberculous treatment have shown that repeat CSF analysis can provide valuable clinical 
guidance with regards to diagnostic accuracy. The sensitivity for acid-fast bacilli staining and 
positive mycobacterial CSF culture can also be improved, after examining multiple samples of 
CSF. 
 
Research in childhood TBM is lacking on the evolution of CSF changes, as determined by serial 





3.2 Research hypotheses: 
 
Repeat CSF analysis in children with possible or probable TBM, does not improve diagnostic 
accuracy. 
 
3.3 Research question: 
 
Does serial lumbar CSF re-sampling influence the diagnostic accuracy of childhood TBM? 
 
3.4 Primary research outcomes:  
 
1. To describe the evolution of CSF parameters analyzed serially, that affect the sensitivity of 
clinical confirmation in children diagnosed with TBM. 
 
3.5 Secondary outcomes: 
 
1. To describe the demographic profile of the study population i.e. age, race, and gender 
2. To describe changes in all CSF parameters on admission, week 1, week 2 and week 3 
3. To identify the optimal timing for CSF re-sampling in TBM suspects with atypical initial 
CSF analysis 
4. To determine which clinical factors are associated with a serial increase in CSF leucocytes 










The study was conducted at Tygerberg Hospital, Cape Town. It is currently the largest hospital in 
the Western Cape, and the second largest hospital in South Africa serving as the academic and 
teaching hospital for Stellenbosch University. It lies within the metropole of Cape Town serving 
2.6 million people, mostly poor communities. Each year, approximately 16 000 neonates and 
children receive inpatient medical care at Tygerberg Hospital and more then 100 000 receive 
specialist medical care as outpatients. 
 
4.2 Study population: 
 
Children prospectively enrolled in previous TBM research studies at Tygerberg Hospital between 
January 1985 and December 2015 were included.  
 
4.2.1 Inclusion criteria 
 
1) All children aged between 3 months and 13 years 
2) Any clinical suspicion of tuberculous meningitis (TBM) 
3) Children with CSF analysis on admission 
4) Children with at least one further CSF analysis at either 1, 2 or 3 weeks post-admission 







4.2.2 Exclusion criteria 
 
1) Children aged less than three months and older than 13 years 
2) Non-tuberculous meningitis 








1) A change in TBM CSF over time 
2) To determine which CSF values over time are suggestive of an alternate diagnosis. 
3) To determine which clinical factors are associated with an atypical TBM trend  
 
4.5 Time frame 
 
A 30-year period between 01 January 1985 and 31 December 2015 
 
4.6 Data collection 
 
The primary sources of data were obtained from an existing TBM database with previously 






This included:  
4.6.1. Demographic data: age, gender, race 
4.6.2. Medical data: BCG, TB contact, HIV status, nutrition 
4.6.3. Clinical data: TBM Stage of disease, duration of symptoms, fever, weight loss, 
vomiting, convulsions, cough, headache, failure to thrive, night sweats, altered 
level of consciousness, GCS on admission, meningeal irritation, raised intracranial 
pressure, brainstem dysfunction, cranial nerve palsies, and focal neurological 
deficit 
4.6.4. Special investigations: Tuberculin skin test, CXR, gastric washings, neuroimaging, 
CSF analysis. The specific CSF characteristics that were collected included CSF 
cell count, CSF glucose concentration, CSF plasma glucose ratio, CSF protein 
concentration, CSF microbiology results including CSF acid fast bacilli 
microscopy, CSF MTB culture, CSF molecular diagnostic result.  
 
4.7 Case-definitions used 
 
4.7.1 Diagnosis of TBM 
Patients was classified as probable or definite TBM according to the uniform research case 
definition based on a scoring system consisting of clinical, CSF, and neuroimaging findings 
(Appendix 2).21 
 
A maximum score of 4 points is assigned to CSF criteria which includes  
1) clear CSF appearance 
2) leucocyte count 10-500 cells/µL 
3) lymphocytic predominance (>50%) 
4) protein concentration >1g/L 











TBM was classified as ‘possible’ when a patient had a diagnostic score of 6–11 when 




TBM was classified as ‘probable’ when patients scored ≥ 12 when neuroimaging was available 




TBM was classified as ‘definite’ when CSF demonstrated acid-fast bacilli and/or positive M. 
tuberculosis culture and/or positive commercial nucleic acid amplification test for M. tuberculosis 
in a patient with symptoms or signs suggestive of the disease.21 
 
4.7.2 TBM Stage: TBM was staged according to the refined British Medical Research Council 
(BMRC) criteria as: 
• Stage I: Glasgow Coma Scale (GCS) of 15 and no focal neurology 
• Stage IIa: GCS of 15 plus focal neurology 
• Stage IIb: GCS of 11-14 with focal neurology 
• Stage III: GCS <1117,18 
 
4.7.3 Atypical TBM CSF trends 
1) CSF lymphocyte count increasing over time 
2) CSF neutrophil count increasing over time 
3) CSF protein count increasing over time 






4.8 Data Management 
 
Only retrospective routinely-collected data from an existing TBM database with previously 
consented studies by the Human Research Ethics Committee of Stellenbosch University (HREC 
reference numbers N10/11/367 and N11/01/006) were analyzed in this study. Data was captured 
on a data collection sheet (Appendix 1). To ensure complete confidentiality and anonymity, every 
patient in the existing TBM database was allocated a unique study number. The data was then 
transferred to an Excel spreadsheet for analysis. All information/data had a separate password 
protected file and this was only known to and accessed by the researchers 
 
4.9 Data Analysis 
 
Data analysis was done in collaboration with the Biostatistics Department at the University of 
Stellenbosch. Statistical analysis was performed using Statistical Package for the Social Sciences 
version 24 (SPSS Inc, Chicago, IL, USA). For numerical variables, mean and standard deviation 
were used for data with a normally distribution; median and interquartile range were used for 
data with a skewed distribution. Categorical variables were described using proportions. The X2 
and one-way ANOVA was used to assess differences between continuous and categorical 
variables respectively. The level of significance was set at the 5% level (p<0.05). Longitudinal 
clustering was done using the median. 
 
To test the validity of the analysis, the cases with “possible” TBM, initially excluded from the 
database, were later compared to the results obtained from the “probable” and “definite” TBM 
cases. The repeat CSF results of the “possible” group were used in the recalculation of the case 







4.10 Ethical considerations 
The study was approved by the Human Research Ethics Committee of Stellenbosch University, 





Chapter 5: Results  
 
In total, 318 children suspected of having TBM were included in this study, fifty-three (17%) 
patients had ‘definite’ TBM and 265 (83%) patients had ‘probable’ TBM. 
 
 Demographic data are shown in Table 1. The mean age at presentation was 36 months (range 2-
180 months), males being slightly more affected than females (52% vs 48 %). There was a 
higher incidence amongst patients of mixed ancestry (251 patients; 79%). The HIV status was 
only available in 111 out of 318 patients (35%). Of these, 4 (4%) patients were HIV-infected. A 
background history of contact with a known household TB source case was found in 219 (69%) 
of patients. 
 
Clinical features present on admission are summarized in Table 2. Prolonged symptom duration 
>5 days (76%), history of fever (63%) and altered level of consciousness (95%) were the most 
frequent presenting symptoms. Weight loss and convulsions was seen in less than half of the 
patients. 
 
The most notable signs on admission were meningeal irritation (96%), abnormal GCS (96%) and 
motor deficit (63%). The majority of patients were classified as BMRC stage IIb (47%) and stage 
III (49%). 
 
The tuberculin skin test was positive in 38% and abnormal chest X-ray findings were present in 
61% of patients. Of these, 49% had findings suggestive of PTB, including intrathoracic 
lymphadenopathy and parenchymal consolidation, whilst the remaining 12% had miliary  
infiltration. Culture for M.tb from gastric washings were positive in 19%. Common 







CSF analysis was performed on admission and repeated at least once at either 1, 2 or 3 weeks 
post-admission. A total of 972 lumbar CSF samples were analyzed. All patients (318) had CSF 
analysis on admission, 260 samples (82%) were taken after 1 week, 198 (62%) after 2 weeks, 
and 196 samples (62%) were collected and analyzed 3 weeks after initiating treatment. Only 91 
patients (29%) had complete CSF analysis done at all four time points. Table 4 summarizes all 
the CSF results on admission and changes in CSF cellular and biochemical parameters over time 
are shown in Figure 1. 
 
On admission, a CSF cell count of 10-500/ µL was found in 276 patients (87%) and lymphocytic 
predominance in 261 (82%). Raised protein concentration of ≥ 1 g/L was found in 299 patients 
(72%). There were too few data available on serum glucose levels (n=56), but 222 (73%) had a 
CSF glucose ≤ 2.2 mmol/L, or CSF glucose/serum glucose ≤ 50%, when available. After one 
week on treatment, the lymphocyte, neutrophil, and protein count had decreased, and the CSF 
glucose concentration increased.  
 
CSF analysis 3 weeks after treatment demonstrated a decline in both lymphocyte and neutrophil 
counts from 143/µL (95% CI, 116.22 -169.82) to 49/ µL (95% CI, 36.53-61.73) and 53/ µL (95% 
CI, 29.39-77.42) to 9/ µL (95% CI, 2.45-16.04) respectively (figure 1a and 1b). The mean CSF 
protein level showed a gradual decrease from 3.29g/L (95% CI, 1.62-4.96) on admission to 
1.85g/L (95% CI, 1.48-2.26) three weeks after initiating treatment (figure1c). The mean CSF 
glucose gradually increased from 1.89 mmol/L (95% CI, 1.65-2.12) on admission to 2.72 
mmol/L (95% CI, 2.59-2.86) after the 3rd week of treatment (figure 1d). Microbiological 
confirmation of M.tb in all CSF samples, either through microscopy, culture or PCR, was 17%. 
 
    
Closer analysis of all data revealed two CSF trends. Eighty-eight (28%) of patients with 
“probable” or “definite” TBM had a typical, expected CSF trend of all cell lines and biochemical 
parameters over the three-week period. Typical CSF trends over time are shown in Figure 2. 
A decrease in lymphocyte count was seen in 206 patients (65%), a decrease in neutrophil count 
was seen in 194 (61%) of patients, a decrease in protein count in 164 (52%) and an increase in 




On admission, a CSF lymphocytic predominance of 167/ µL (95% CI, 145.65-188.29) was found 
in 206 patients (65%), this decreased with more than half after the first week to 77/µL (95% CI, 
63.08-91.90) and further decreased over the next two weeks to a count of 39 / µL (95% CI, 
45.60-64.80) at the end of the 3 weeks (figure 2a). A mean CSF neutrophil count also 
demonstrated a decline 3 weeks after treatment from 66 / µL (95% CI, 50.58-80.98) to 4 / µL 
(95% CI, 1.75-5.94), with more than three quarter decline after 1 week (figure 2b). The mean 
CSF protein level showed a gradual decrease from 4.14g/L (95% CI, 2.85-5.43) on admission to 
1.35g/L (95% CI, 1.05-1.64) three weeks after initiating treatment (figure 2c). The mean CSF 
glucose gradually increased form 1.68 mmol/L (95% CI, 1.56-1.79) on admission to 2.71 
mmol/L (95% CI, 2.60-2.82) after the 3rd week of treatment (figure 2d). 
 
A total of 230 (72%) patients were identified that had atypical CSF trends, of these 112 (49%) 
patients had an atypical lymphocyte trend, 123 (53%) an atypical neutrophil trend, 152 (66%) an 
atypical protein trend and 22 (10%) patients an atypical glucose trend. Figure 3 demonstrates 
atypical CSF changes in cellular and biochemical parameters over time. 
 
On admission, a mean lymphocytic count of 86 / µL (95% CI, 68.41-103.39) increased to 150 µL 
(95% CI, 126.81-175.00) after one week, followed by a decreased over the next 2 weeks to 74/ 
µL (95% CI, 55.70-91.51) (figure 3a). An initial mean neutrophil count of 12/ µL (95% CI, 7.03-
17.44), increased to 38/ µL (95% CI, 26.25-49.07) after 1 week, then decreased to 13 µL (95% 
CI, 8.32-17.36) and remained at a mean of 13/ul (95% CI, 5.50-20.84) after the 3 weeks of 
treatment (figure 3b). A mean protein concentration of 1.45 g/L (95% CI, 1.25-1.66) on 
admission increased over the first 2 weeks to a mean of 2.81g/L (95% CI, 1.81-3.82) and 
remained high at 2.11g/L (95% CI, 1.59-2.62) at the end of the treatment period (figure 3c). A 
mean glucose of 3.4 mmol/L (95% CI, 2.75-4.02) decreased to 1.74 mmol/L (95% CI, 1.32-2.16) 
after 1 week, followed by an increased over the next 2 weeks to 2.46 mmol/L (95% CI, 2.25-
2.67) (figure 3d). 
 
In the atypical lymphocyte trend group, 23 (21%) patients had “definite TBM and 89 (79%) 
“probable” TBM. Twenty-two (18%) of the 123 patients in the atypical neutrophil tend group 




protein trends 24 (16%) had “definite” TBM and 128 (86%) “probable” TBM. 128. Similar to 
the atypical lymphocyte trend group, 22 (23%) of the patients with an atypical CSF glucose trend 
had “definite” TBM and the remaining 17 (79%), “probable” TBM. 
 
Univariable analysis was performed to predict variables that were independently associated with 
these atypical CSF trends. Table 5 summarizes the findings.  
A history of prolonged duration of illness >5 days (OR 2.30; 95% CI, 1.26-4.17; p=0.01), cranial 
nerve palsy (OR 1.77; 95% CI, 1.06-2.95; p=0.03) and CSF neutrophil predominance on 
admission (OR 2.90; 95% CI, 1.61-5.20; p<0.01) were significantly associated with an atypical 
CSF lymphocyte trend (CSF lymphocytes increasing between admission and follow-up CSF 
analysis up to 3 weeks post-admission). Similarly, a positive tuberculin skin test (OR 1.60; 95% 
CI 0.99-2.57; p=0.05) and a CSF lymphocyte count of >50% (OR 3.59; 95% CI 1.74-7.41; 
p<0.01) were significantly associated with an atypical CSF neutrophil trend (CSF neutrophils 
increasing between admission and follow-up CSF analysis up to 3 weeks post-admission). Only 
an admission CSF protein level >1g/L predicted an atypical trend of serially increasing CSF 
protein subsequent to admission (OR 3.30; 95% CI, 1.96-5.56; p<0.01). No variables were found 
to be associated with an abnormal CSF glucose trend. 
 
In order to determine the value of serial CSF when scoring suspects using the uniform TBM 
research case definition, points for CSF features were allocated at admission and weeks 1 to 3. 
During the study period, in addition to the 318 children included with ‘definite’ and ‘probable’ 
TBM, there were 44 children identified with ‘possible’ TBM. In 6 of the children with ‘possible’ 
TBM at admission (14%), re-scoring following repeat CSF analysis improved their research case 
definition status to ‘probable’ TBM. 
 
Longitudinal clustering was performed using the four CSF variables measured at four time points 
in our study population (n=318). There were only 91 patients with complete information in all 16 
measurements (4 variables at 4 time points) k-medians partition cluster analysis was done to 
provide the classification in k groups based on the median profile across the 16 variables. To 
enhance the classification 9 more variables were added to the dataset. This was the difference 




add in separating different possible profiles. The median partitioning was used since there were 
some outliers in the data i.e. CSF protein. Figure 4 shows the three median base clustering 
graphs. 
 
The three-group median base clustering demonstrated distinct profiles with different trajectories 
over the first two time points. There is a low group (n=150), a start high group (n=88) and a 
middle to high group (n=80). The low group is about half of the sample (n=318) and the other 
two groups about 25% each. The changes between time points seemed to be an important feature 
between these three groups. This clustering analysis demonstrated that group 3 followed an 
“atypical” trend for TBM suspects. The CSF median for lymphocytes, neutrophils, and protein 
increased over the first week, in contrast to group 1 which followed the typical expected trend. 




Chapter 6: Discussion 
  
Repeat lumbar CSF does not improve the early diagnosis of childhood TBM, but it does affect the 
sensitivity of clinical confirmation in children diagnosed with TBM based on the uniform TBM 
research case definition.                                                                    
 
In this study, serial lumbar CSF parameters analyzed in children with “probable” and “definite” 
tuberculous meningitis, showed a steady decline in lymphocyte and protein count, a more rapid 
decrease in neutrophil count, with a rapid increase in CSF glucose concentration, similar to adult 
studies.25-27 CSF glucose concentration was the only parameter that normalized over the 3-week 
time period with concentrations returning to >2.2 mmol/L one week post-initiation of treatment. 
TBM is a chronic inflammatory response and CSF is expected to take weeks to normalize whilst 
rapid normalization is expected in non- tuberculous meningitis.29  
 
Mycobacterial confirmation was found in 17% of initial CSF samples. This is in agreement with 
previous studies that found a frequency of 12-31% 7,13,14,24,35 and reflects normal clinical practice 
where most TBM cases will not have microbiologic confirmation of .M.tb due to the paucity of 
bacilli in the CSF. In contrast, one study had positive CSF microscopy or culture in 69% of 
patients after multiple samples were taken following initiation of treatment.15 It has been 
recognized that sensitivity of acid-fast staining and M.tb culture is directly dependent on the 
number and volume of CSF samples.15 Repeat CSF samples, unfortunately, did not include 
microscopy, culture or PCR, which could have influenced microbiological confirmation in our 
study. 
 
The mean age of our study population was ±36 months, boys and girls being equally affected. 
This is comparable to several studies that indicate that TBM mainly effect children < 5years of 
age, a peak age between 24 and 48 months, with no gender preference. 6-8,13, 15, 22,24 A high 
incidence was seen amongst patients of mixed ancestry (79.4%), and no patients of European 
descent were part of the study. This population distribution is representative of our hospitals 




 The HIV status was unfortunately only available in 35% of our patients with 4% being infected. 
This compares to literature that found 1-10% of patients being infected, 8, 22,24 but is in contrast to 
one study that found that 72% of microbiologically-confirmed TBM patients was HIV positive.30 
Our study time frame dates back to 1985, two years after Acquired Immunodeficiency Syndrome 
(AIDS) was diagnosed for the first time in South Africa, which probably contributes to the low 
number of patients tested for HIV. HIV-positive patients have a higher frequency of a non-
inflammatory CSF profile that may influence the early diagnosis.30 Co-infected patients also 
have a higher mortality rate and are more susceptible to MDR-TB, thus excluding them from our 
study. There was strong epidemiological evidence of history of contact with a household adult 
TB source case in 219 (69%) patients. This result is expected in a TB endemic environment like 
the Western Cape Province of South Africa. A background history with a known household TB 
source usually ranges between 30 -53 %.7,13-15,24 
 
The most frequent symptoms and signs on admission included prolonged symptom duration >5 
days, fever, meningeal irritation, altered level of consciousness and motor deficit, similar to 
previous studies. 7,13,15A history of weight loss, defined as a decrease in weight, growth plateau, 
or slower weight gain to age- and sex-matched controls on the WHO weight for age charts, were 
found in less than half of our patients. This is not consistent with previous findings that 88-90% 
of patients had either weight loss or poor weight gain for weeks to months before 
presentation.7,24 It is recognized that TBM is frequently accompanied by miliary tuberculosis, 
although the pathogenesis remains unclear.11,14,24 Our study found a miliary CXR pattern in 12% 
of patients.  
 
Based on refined British Medical Research Council (BMRC) criteria,16,17 almost half of the 
patients presented with advanced disease (stage 3), similar to previous reports.7,15 The delayed 
presentation, especially in our setting, can in part due to social reasons including lack of education, 
limited access to health-care facilities and also due to misinterpretation of the initial non-specific 
symptoms in young children by healthcare workers leading to delayed diagnosis. Tygerberg 





The study supports the typical characteristic lumbar CSF findings of a cell count of 10-500/ µL 
(87%) with lymphocytic predominance (82%), raised protein concentration of ≥ 1 g/L (72%) and 
CSF glucose ≤ 2.2 mmol/L, or CSF glucose/serum glucose ≤ 50% (70%).7,13,19, 21-23 
 
Atypical fluctuations in CSF cell count, protein and glucose results are common during the early 
weeks of anti-tuberculous therapy.13 Our study had a total of 230 (72%) patients with atypical 
CSF trends over the time period. A temporary deterioration of CSF findings does not necessarily 
indicate inappropriate therapy or a wrong diagnosis. 
 
A history of prolonged illness >5days, cranial nerve palsy, and a CSF neutrophil predominance 
were significantly associated with an increase in CSF lymphocyte count over the 3 weeks. A 
positive tuberculin skin test and a CSF lymphocyte predominance on initial lumbar puncture 
were significantly associated with an atypical neutrophil trend increasing between admission and 
follow-up CSF analysis 3 weeks post-admission. An atypical CSF protein level >1g/L on 















Our study included a large TBM sample size with extensive data that was collected 
prospectively. The data included CSF samples at different time points which makes it ideal for 




As this was a retrospective evaluation of prospectively collected data, the biggest limiting factor 
was missing data. This ranged from relevant history of symptoms that was not taken or 
documented adequately, lumbar puncture that was not repeated or serum glucose not being 
measured for comparison.  
 
The study was limited by the small number of patients with serum glucose measurements and 
HIV co-infection. Anti-retroviral therapy (ART) status of HIV infected patients was unknown. 
Important data that was not collected included a history of previous TB and BCG vaccination. 
External validity was poor and needs to be assessed. This may possibly lead to bias and not 











Chapter 8: Recommendations 
 
1. In children with suspected TBM, serial CSF cultures may increase the diagnostic 
accuracy when the uniform research case definition for TBM is used. 
2. In TBM suspects, the serum glucose should be measured with CSF analysis to assess the 
CSF to plasma glucose ratio 
3. Clinicians should always maintain a high index of suspicion amongst all children 
presenting with non-specific symptoms, especially in TB endemic areas, and initiate 
TBM treatment early to prevent sequelae.  





Chapter 9: Conclusion 
 
Knowledge of the different CSF responses during the course of TBM therapy is important in 
clinical decision making. From our study, the evolution of lumbar CSF in patients with 
“probable” and “definite” TBM, provides a standardize trend/predicted model, for comparison of 
follow up CSF analysis. Repeat lumbar CSF in TBM suspects can demonstrate different trends 
over time. The typical trend is a gradual decline in CSF lymphocyte, neutrophil, and protein 
count whilst the CSF glucose rises steadily. This slow change in lymphocytic, protein and 
neutrophil count unfortunately limits their clinical use. 
  
 It is not abnormal for the CSF lymphocyte, neutrophil, and protein count to rise initially after 
treatment initiation, which can be seen as an atypical trend for TBM. We identified certain 
clinical features that are significantly associated with atypical CSF change over time. Serial 
lumbar CSF analysis improves the diagnosis of childhood tuberculous meningitis when the 
uniform TBM research case definition’s scoring system is applied. It however does not improve 
earlier diagnosis and outcome of TBM in children, and it could cause confusion if an atypical 
trend is found. CSF analysis on admission remains the most valuable diagnostic tool and repeat 
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Table 1 Demographic data  
Variable  
Age in months (mean (95% CI) 36.34(30.68-42.01) 
Gender 
Male (n/N, %)# 





Black (n/N, %)# 





Positive HIV (n/N, %)# 
 
4/111(4) 
TB contact* (n/N, %)# 219/318(69) 
CI = confidence interval; HIV = human immunodeficiency 
virus; TB = tuberculosis 
* Defined as a history of recent close contact with a person 
with infectious TB within the past year 


































Table 2 Clinical features at presentation 
 
Variable Frequency (%) 
Symptom duration >5 days 241/318(76) 
Presenting symptoms 
History of fever# 
 
187/296(63) 
Weight loss# 127/296(43) 
Vomiting# 155/296(53) 
Convulsions# 131/296(44) 
Cough >2 weeks 135/318(43) 
Headache# 77/296(26) 
FTT+, night sweats, cough 
>2weeks 
144/318(45) 
Altered level of consciousness 303/318(95)  
 















Raised intracranial pressure# 78/316(25) 
Brainstem dysfunction 123/318(39) 
Cranial nerve palsies 81/318(26) 












TBM = tuberculous meningitis; FTT = failure to thrive; GCS = 
glascow coma scale 
*Uniform research case definition from Marais et al. 
+ Defined as weight loss, growth plateau, or slower weight gain to 
age- and sex-matched controls on the WHO weight for age charts 
# The denominator varies according to available data 

















Table 34 Results of other TB Investigations  
Investigations Frequency (%) 
Tuberculin skin test reactive# 115/303(38) 
CXR findings  




















CXR = chest x-ray; PTB = pulmonary tuberculosis, TB = 
tuberculosis; Mtb = Mycobacterium Tuberculosis; CT = computed 
tomography; MRI = magnetic resonance imaging  





  Table 4: Cerebrospinal fluid findings on admission  
Results Frequency(n/N) (%) 
Cells 10-500/µL 
Lymphocytes ≥ 50% 
Protein ≥ 1 g/L 
CSF:serum glucose ratio ≤ 50% or 
CSF glucose ≤ 2.2 mmol/L 







Mtb = Mycobacterium Tuberculosis 









Table 5: Variables associated with an abnormal CSF 
trend 
   
Characteristics OR (95% CI) P value  
Atypical lymphocyte trend 
Prolonged duration of illness >5 days 
Cranial nerve palsy 
CSF neutrophil predominance on admission 
 
Atypical neutrophil trend 
Positive tuberculin test 
CSF lymphocytes ≥ 50% 
 
Atypical protein trend 




























List of Figures 
Figure 1: Mean values and 95% CI of cerebrospinal fluid (CSF) lymphocyte count, 
neutrophil count, protein, and CSF glucose over 3 weeks.   
 
       
 
        
Figure 1. Mean values and 95% CI are shown of cerebrospinal fluid (CSF) lymphocyte count, neutrophil count, 
protein, and CSF glucose over the treatment period.  A, Total CSF Lymphocyte over the treatment period. B, Total 
CSF neutrophil over the treatment period. C, Total CSF protein over the treatment period. D, Total CSF glucose 































































































Figure 2: Mean values and 95% CI are shown of all the typical cerebrospinal fluid (CSF) 
lymphocyte count, neutrophil count, protein, and CSF glucose over the treatment period.   
 
        
 
 
        
Figure 2. Mean values and 95% CI are shown of all the typical cerebrospinal fluid (CSF) lymphocyte count, 
neutrophil count, protein, and CSF glucose over the treatment period.  A, Typical CSF Lymphocyte over the 
treatment period. B, Typical CSF neutrophil over the treatment period. C, Typical CSF protein over the treatment 




























































































Figure 3: Mean values and 95% CI are shown of all the atypical cerebrospinal fluid (CSF) 
lymphocyte count, neutrophil count, protein, and CSF glucose over the treatment period.  
 
        
 
 
        
 
Figure 3. Mean values and 95% CI are shown of atypical cerebrospinal fluid (CSF) trends for lymphocyte count, 
neutrophil count, protein, and CSF glucose over the treatment period.  A, Atypical CSF Lymphocyte trend over the 
treatment period. B, Atypical CSF neutrophil trend over the treatment period. C, Atypical CSF protein trend over the 

































































































Figure 4: Three group clustering median values of available cerebrospinal fluid (CSF) 
lymphocyte count, neutrophil count, protein, and CSF glucose over the treatment period.   
 




            
 
Figure 4. Three group clustering median values of available cerebrospinal fluid (CSF) lymphocyte count, 
neutrophil count, protein, and CSF glucose over the treatment period.  A, CSF Lymphocyte over the treatment 
period. B, CSF neutrophil over the treatment period. C, CSF protein over the treatment period. D, CSF glucose 






















csf_lymph0 csf_lymph1 csf_lymph2 csf_lymph3
Variables
_clus_3 = 1 _clus_3 = 2













csf_neutr0 csf_neutr1 csf_neutr2 csf_neutr3
Variables
_clus_3 = 1 _clus_3 = 2















csf_prot0 csf_prot1 csf_prot2 csf_prot3
Variables
_clus_3 = 1 _clus_3 = 2

















csf_gluc0 csf_gluc1 csf_gluc2 csf_gluc3
Variables
_clus_3 = 1 _clus_3 = 2




List of Appendices 
Appendix 1: Diagnosis of TBM: universal case definition20 
 Diagnostic score 
Clinical criteria (Maximum category score=6) 
Symptom duration of more than 5 days 4 
Systemic symptoms suggestive of TB (1 or more of): weight 
loss/(poor weight gain in children), night sweats or persistent 
cough > 2 weeks 
2 
History of recent close contact with an individual with pulmonary 
TB or a positive TST/IGRA in a child <10 years 2 
Focal neurological deficit (excluding cranial nerve palsies) 1 
Cranial nerve palsy 1 
CSF criteria (Maximum category score=4) 
Clear appearance 1 
Cells: 10–500 per µL 1 
Lymphocytic predominance (>50%) 1 
Protein concentration greater than 1 g/L 1 
CSF to plasma glucose ratio of less than 50% or an absolute CSF 
glucose concentration less than 2.2mmol/L 1 
Cerebral imaging criteria (Maximum category score=6) 
Hydrocephalus (CT and/or MRI) 1 
Basal meningeal enhancement (CT and/or MRI) 2 
Tuberculoma (CT and/or MRI) 2 
Infarct (CT and/or MRI) 1 
Pre-contrast basal hyperdensity (CT) 2 
Evidence of tuberculosis elsewhere (Maximum category score=4) 
Chest radiograph suggestive of active TB (excludes miliary TB) 2 
Chest radiograph suggestive of miliary TB 4 
CT/ MRI/ US evidence for TB outside the CNS 2 
AFB identified or M. tuberculosis cultured from another source 
i.e., sputum, lymph node, gastric washing, urine, blood culture 4 
Exclusion of alternative diagnoses- An alternative diagnosis must be confirmed 
microbiologically, serologically or histopathologically 
Definite TBM =AFB seen on CSF microscopy, positive CSF M. tuberculosis culture, or 
positive CSFM. tuberculosis commercial NAAT in the setting of symptoms/signs suggestive of 
meningitis; or AFB seen in the context of histological changes consistent with TB brain or 
spinal cord together with suggestive symptoms/signs and CSF changes, or visible meningitis 
(on autopsy). 
Probable TBM = total score of ≥12 when neuroimaging available 
                           = total score of ≥10 when neuroimaging unavailable 
Possible TBM = total score of 6-11 when neuroimaging available 




Appendix 2: Data collection sheet 
 
 Admission Week 1 Week 2 Week 3 
Basic information     
Inclusion number     
Age in months     
Gender     
Definite or probable TBM     
TBM stage     
Duration of symptoms (days)     
HIV status     
Neuroimaging     
Hydrocephalus y/n     
Communicating/Non-
communicating 
    
Basal enhancement y/n     
Infarction y/n     
CSF analysis     
CSF volume taken (ml)     
CSF macroscopic appearance      
CSF Polymorphs cell/mm3     
CSF Lymphocytes cell/mm3     
CSF protein g/L     
CSF glucose mmol/L     
Other investigations     
Extra neural B culture pos/neg     
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+27 21 400 3981). Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital 
manager. Ethics approval is required BEFORE approval can be obtained from these health authorities. 
We wish you the best as you conduct your research. 
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